Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL2734250 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4465974-A1 | VITAMIN NANOCLUSTERS AS THERAPEUTIC AND NUTRACEUTIC AGENTS AND CARRIERS | Fondazione Istituto Italiano di Tecnologia (IT) | 2024-11-27 | — | — | EP | claimed |
| WO-2023135583-A1 | VITAMIN NANOCLUSTERS AS THERAPEUTIC AND NUTRACEUTIC AGENTS AND CARRIERS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2023-07-20 | — | — | WO | claimed |
| WO-2026107515-A1 | INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME | DIASOME PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4465974-A1 | VITAMIN NANOCLUSTERS AS THERAPEUTIC AND NUTRACEUTIC AGENTS AND CARRIERS | Fondazione Istituto Italiano di Tecnologia (IT) | 2024-11-27 | — | — | EP | disclosed |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2023135583-A1 | VITAMIN NANOCLUSTERS AS THERAPEUTIC AND NUTRACEUTIC AGENTS AND CARRIERS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2023-07-20 | — | — | WO | disclosed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-3952904-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | SMN1; SMN2 2242/4885NR5A2 1348/4885NR5A1 892/4885 |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | SMN1; SMN2 219/4885NR5A2 4382/4885NR5A1 4075/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | SMN1; SMN2 3424/4885NR5A2 2982/4885NR5A1 2102/4885 |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | SMN1; SMN2 2814/4885NR5A2 2432/4885NR5A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.